Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
复制标题
DOI：
10.1016/j.jhepr.2020.100123
复制
发表时间：
2020-08-01
期刊：
影响因子：
8.3
通讯作者：
Dalekos, George N.
中科院分区：
文献类型：
--
作者：
Arvaniti, Pinelopi;Giannoulis, George;Dalekos, George N.
背景与目的：自身免疫性肝炎（AIH）是一种病因不明的疾病，对免疫抑制反应良好。然而，在临床中，似乎
Background & aims: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that